Cogent Biosciences

We're excited to share that the FDA has accepted our NDA for bezuclastinib in patients with NonAdvanced SM. We’re thankful to the patients, families, investigators & the entire Cogent team who made this significant achievement possible. Read more: bit.ly/4cLC2Vi

Cogent is driven by our commitment 2 advancing therapies 4 those living w/#SystemicMastocytosis & #GIST. On #RareDiseaseDay , we wore stripes 2 raise awareness, show our support 4 the #SM & #GIST communities, & reflect on the people who inspire our work each day. #ShowYourStripes

We’re excited to be at the #AAAAI26 ! Today we’re presenting data from 6 bezuclastinib posters. Read the release bit.ly/4u27RiQ and find the posters here bit.ly/40x1vue. If you missed us at the poster sessions come see us in booth 917 in the Exhibit Hall!

Our team is heading to the American Academy of Allergy, Asthma & Immunology Annual Meeting where we’re presenting six SUMMIT posters in NonAdvanced SM. The Exhibit Hall opens Feb 27 and our posters are Feb 28 at 9:45am ET. We hope to see you there! #NonAdvSM #AAAAI26

Today we shared our 4QFY 2025 financial results and recent business highlights. We’re proud of our progress and look forward to what’s ahead. Read the full press release here: bit.ly/4kIQvDm

We’re pleased 2 announce that the FDA has granted Breakthrough Therapy Designation for bezuclastinib in combo w/sunitinib for patients w/Gastrointestinal Stromal Tumors #GIST who have received prior treatment w/imatinib. Learn more: bit.ly/4q50h3L #raredisease #NDA #RTOR

We’re pleased to announce that the FDA has agreed to accept our GIST NDA submission under their RTOR program. Read more here: bit.ly/3Nwf4H6 #NDA #GIST #RTOR

This morning, we announced our 2026 anticipated commercial and clinical milestones for bezuclastinib & our precision therapies portfolio. Read today’s release here: bit.ly/4jF4gTd and listen to tomorrow’s #JPM26 webcast here: bit.ly/3LqsK5S

Our CEO, Andrew Robbins, will present at #JPM26 on Tuesday, January 13th, at 8:15 am PT/11:15am ET. Tune in to the live webcast on our website here: investors.cogentbio.com/events

Today we announced our first New Drug Application with bezuclastinib for #NonAdvSM to the U.S. FDA. This is an important milestone for patients and Cogent, and we are thrilled to have taken this next step. Read more: bit.ly/45wNzmN

Join our webcast today at 8:00am ET & hear more on our SUMMIT data in #NonAdvSM shared at #ASH25. We’ll also review this AM's positive APEX top-line results in #AdvSM; our 3rd positive bezu pivotal trial in 2025! Join: bit.ly/4iDz2v0 Today's PR: bit.ly/48KrNwZ

We shared full SUMMIT data today at #ASH25 highlighting bezu’s clear clinical benefit across all symptom domains & that reducing objective measures of disease correlates w/ improvement in symptom severity. PR: bit.ly/4iKKCof. Webcast: bit.ly/4iDz2v0

We're headed to Orlando for the @ASH_hematology 67th Annual Meeting and Expo. We’re looking forward 2 engaging with the #hematology community & sharing our latest updates with bezuclastinib in #NonAdvSM & new research from our JAK2 inhibitor. Come see us in Booth 1981! #ASH25

We’re headed to the @Jefferies Global Healthcare Conference in London next week. You can listen to our presentation on Wed, Nov 19 at 11:30am GMT/6:30am ET here: bit.ly/4p4hPge #JefferiesHealthcare

Today we shared landmark results from our Ph 3 PEAK trial in #GIST. We are deeply grateful 2 the patients, families & researchers whose participation helped make this possible. Read the release: bit.ly/3JL9LlE . Join our webcast at 8am ET: bit.ly/3Xlop6c

Today we reported our 3Q25 financial results. Read the PR here: bit.ly/4nwUAuh. We also announced 2 oral presentations & a poster with bezuclastinib at #ASH25 & a poster with our newest program, a JAK2 V617F mutant-selective inhibitor. Read more: bit.ly/4hLBO10.

The FDA has granted BTD for bezuclastinib in #NonAdvSM patients previously treated with avapritinib as well as in patients with SSM; populations with no currently approved standard of care. We'll also report PEAK TLR in Nov & APEX TLR in Dec. Read the PR: bit.ly/4hjm7xD

We’re proud to be one of this year’s sponsors of the European Competence Network on Mastocytosis (ECNM) annual meeting. The team is here and looking forward to connecting with systemic #mastocytosis disease experts. #NonAdvSM #AdvSM

Our Medical Affairs team is at the 2025 Society of Hematologic Oncology Annual Meeting (SOHO 2025) in Houston. Stop by booth #118 to learn more. See you there! #NonAdvSM #AdvSM

Tune in next week on Wed, Sept 3 at 9:00am ET to listen to our fireside chat at Citi’s 2025 Biopharma Back-to-School Conference. Register and join here bit.ly/3HFbBDF.